June 7, 2018 / 1:01 AM / a year ago

Gilead unit strikes out in bid to invalidate Juno cancer treatment patent

A unit of Gilead Sciences Inc on Wednesday lost a bid to invalidate a patent on a novel cancer treatment owned by the Memorial Sloan Kettering Cancer Center in New York City.

The U.S. Court of Appeals for the Federal Circuit affirmed a determination by the Patent Trial and Appeal Board that Gilead’s Kite Pharma Inc failed to show the Sloan Kettering patent was invalid on obviousness grounds.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2Hpcg75

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below